MICROCIDE PHARMACEUTICALS
MICROCIDE PHARMACEUTICALS
Industry:
Biotechnology Medical
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Global Site Tag Organization Schema IPv6 Google Maps
Similar Organizations
Berk Pharmaceutical
Berk Pharmaceutical is a Pharmaceuticals company.
pharmaceutical industry
pharmaceutical industry is a Medical company.
More informations about "Microcide Pharmaceuticals"
Microcide Pharmaceuticals - Crunchbase Company Profile & Funding
Microcide Pharmaceuticals is a Medical company. There is no recent news or activity for this profile. Who are Microcide Pharmaceuticals's competitors? Alternatives and possible competitors to Microcide Pharmaceuticals may include CollaGenex Pharmaceuticals, pharmaceutical …See details»
Microcide Pharmaceuticals - PitchBook
Developer of antimicrobials for the treatment of bacterial, fungal and viral infections. The company works in the discovery and development programs addressing the growing problem of bacterial drug resistance and the need for …See details»
Microcide Takes Over Althexis; Firm Secures $60M Financing
Jul 31, 2001 · Microcide Pharmaceuticals Inc. plans to take over The Althexis Company Inc. in a stock swap worth about $22 million, and the new firm has nailed down $60 million in private …See details»
Microcide Pharmaceuticals - Products, Competitors, Financials ...
Developer of anti-microbial compounds for the treatment of bacterial infectious diseases. These novel pharmaceuticals are targeted at drug-resistant pathogens, or those diseases no longer …See details»
The Standard: Microcide Pharmaceuticals, Inc.
Microcide Pharmaceuticals puts disease under the microscope. The firm is developing new antimicrobials to fight drug-resistant bacteria, viruses, and systemic fungal infections. …See details»
Microcide-Althexis: Merge to License :: Medtech Insight
Sep 1, 2001 · With Microcide's cephalosporin, technology-based Althexis would get the product focus it lacked. And the deal comes with $60mm in new money from investors who've bought …See details»
Microcide Pharmaceuticals Stock Price, Funding, Valuation, …
See Microcide Pharmaceuticals's detailed income statement and balance sheet. Find out their revenue, expenses and profit or loss over the last fiscal year.See details»
Microcide Pharmaceuticals - Drug pipelines, Patents, Clinical trials ...
Oct 1, 2024 · Explore Microcide Pharmaceuticals with its drug pipeline, therapeutic area, technology platform, 5 literature.See details»
Microcide Pharmaceuticals Inc. - BioCentury Company Profiles
Feb 6, 2023 · Microcide Pharmaceuticals Inc. - BioCentury Company Profiles for the biopharma industrySee details»
BioCentury - Skaletsky back into public life
Aug 6, 2001 · The merger between Microcide Pharmaceuticals Inc. and privately held Althexis Co. Inc. does not bring old-timer MCDE any closer to a marketed product, but it does provide …See details»
James Rurka – Microcide Pharmaceuticals Inc (mcde)
Jan 10, 2001 · JAMES E. RURKA, President, and Chief Executive Officer, Microcide Pharmaceuticals, Inc. Before joining Microcide Pharmaceuticals in February 1994, Mr. Rurka …See details»
John Lopes - President - Microcide, Inc. | LinkedIn
Connect and collaborate with scientific and commercialization communities connected with novel products and new technologies in microbial control …See details»
Research programme: anti-infectives - Essential …
Microcide Pharmaceuticals (later Essential Therapeutics) and Coelacanth Corporation (later Lexicon Pharmaceuticals) formed a collaboration under a jointSee details»
Microcide Pharmaceuticals - Tech Stack, Apps, Patents & Trademarks
Microcide Pharmaceuticals is actively using 29 technologies for its website, according to BuiltWith. These include Viewport Meta, IPhone / Mobile Compatible, and SPF.See details»
Will new antibiotic classes solve multidrug resistance?
May 21, 2021 · This is especially so for Gram-negative bacteria many of which the U.S. Center for Disease Control (CDC) and World Health Organization (WHO) consider serious or urgent …See details»
Olga Lomovskaya - REVIVE
Olga Lomovskaya is Co-Founder and Senior Vice-President of Discovery and Clinical Microbiology at Qpex Biopharma. Her industrial career started in 1995 with her working at …See details»
Prospects for plant-derived antibacterials | Nature Biotechnology
Dec 1, 2006 · Instead of pathogen-specific, somatically generated antibodies, plants evolved a relatively limited array of genomically encoded receptors to recognize specific pathogens, and …See details»
MC-207110 Daiichi Seiyaku/Microcide Pharmaceuticals.
Feb 1, 2001 · Microcide and Daiichi are collaborating on the discovery of new bacterial efflux pump inhibitorsfor the treatment of drug-resistant Pseudomonas aeruginosa and other …See details»
MC-207110 Daiichi Seiyaku/Microcide Pharmaceuticals
Microcide and Daiichi are collaborating on the discovery of new bacterial efflux pump inhibitorsfor the treatment of drug-resistant Pseudomonas aeruginosa and other bacterial infections.See details»
Interplay between Efflux Pumps May Provide Either Additive or ...
Several combinations of efflux pumps have been studied: (i) simultaneous expression of a single-component efflux pump, which exports antibiotics into the periplasm, in combination with a …See details»